A Study of Pyrotinib Combined With Capecitabine for Metastatic HER-2 Positive Colorectal Cancer

Inclusion Criteria: 1. Patients should be histologically diagnosed with metastatic CRC and after receiving at least two standard treatment regimens； 2. Patients with HER2 positive； 3. Metastatic colorectal cancer (stage Ⅳ, T1-4N0-2M1)； 4. Life expectancy is at least 6 months 5. ECOG score 0-1； 6. The functional level of the major organs must meet the following requirements (no blood transfusion within 2 weeks prior to screening, no use of leukocytes or platelets)： Exclusion Criteria: 1. The histopathological type is mucinous adenocarcinoma or ovarian implant metastasis； 2. Patients who have previously been treated with anti-Her2-targeted drugs； 3. Patients with surgical opportunity or potential for surgical treatment； 4. Patients with a high risk of bleeding or perforation due to a tumor that has apparently invaded adjacent organs (including large vessels) of the colorectal lesion or who have developed fistulas； 5. Patients with any severe and/or uncontrolled disease; 6. Patients with any or present brain metastases； 7. Women who were pregnant or breast-feeding.